title: [Role of rifaximin in the treatment of hepatic encephalopathy].
abstract: Hepatic encephalopathy (HE) is a frequent and serious complication of liver cirrhosis. In addition to correction of the precipitating factors, the most commonly used treatments are non-absorbable disaccharides and rifaximin. Many of the recommendations are based on current clinical practice and there are few randomized controlled trials. Currently, rifaximin should be initiated during an episode of EH if, after 24-48 hours of non-absorbable disaccharide therapy, there is no clinical improvement. In recurrent EH, it is advisable to add rifaximin in patients under non-absorbable disaccharide therapy who develop a new episode. Currently, standard treatment with rifaximin for minimal EH is not recommended. Rifaximin is effective in the acute treatment of overt encephalopathy and in preventing recurrence.
authors.affiliation: Unitat d'Hepatologia, Servei de l'Aparell Digestiu, Hopsital de Sabadell. Corporació Sanitària Parc Taulí. Universitat Autònoma de Barcelona, Sabadell, Barcelona, España; CIBERehd, Instituto de Salud Carlos III, Madrid, España.
authors.forename: Jordi
authors.initials: J
authors.lastname: Sanchez-Delgado
authors.affiliation: Unitat d'Hepatologia, Servei de l'Aparell Digestiu, Hopsital de Sabadell. Corporació Sanitària Parc Taulí. Universitat Autònoma de Barcelona, Sabadell, Barcelona, España; CIBERehd, Instituto de Salud Carlos III, Madrid, España. Electronic address: mmiquel@tauli.cat.
authors.forename: Mireia
authors.initials: M
authors.lastname: Miquel
mesh_terms: D006501:Hepatic Encephalopathy / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D012008:Recurrence; D012294:Rifamycins / Q000627:therapeutic use*; D000078262:Rifaximin
chemical_list: D012294:Rifamycins; D000078262:Rifaximin
keywords: Encefalopatia hepatica; Hepatic encephalopathy; Rifaximin; Rifaximina